NEW YORK (GenomeWeb News) – Plant genomics firm Evogene plans to go public in the US with an initial public offering of up to $60 million.

The company, which trades on the Tel Aviv Stock Exchange, filed to go public with the US Securities and Exchange Commission late on Monday, saying it plans to list on the New York Stock Exchange under ticker symbol "EVGN."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.